Literature DB >> 16571367

Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.

Bun-Hee Lee1, Yong-Ku Kim, Sun-Hwa Park.   

Abstract

OBJECTIVE: To assess the effectiveness of substituting aripiprazole for other antipsychotic drugs taken by stable schizophrenic patients suffering from antipsychotic agent-induced symptomatic hyperprolactinemia.
METHODS: Seven female schizophrenic patients with symptomatic hyperprolactinemia (167.6+/-58.0 microg/L) were recruited to take part in an 8-week open label trial of aripiprazole (10-20 mg/day) as a replacement for amisulpride or risperidone. Efficacy was assessed via PANSS and CGI-I scores. Serum prolactin levels were measured at baseline, week 4, and week 8. Data were collected from November, 2004 to May, 2005.
RESULTS: At the end of weeks 4, serum prolactin levels were normalized (8.8+/-5.5 microg/L) and hyperprolactinemic symptoms were resolved in all patients. However, aripiprazole treatment was discontinued within 6 weeks for 2 of the 7 subjects due to aggravated auditory hallucinations.
CONCLUSION: Results from this admittedly small-scale open-label study indicate that switching to aripiprazole may be useful for resolving antipsychotic-induced hyperprolactinemia and associated symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16571367     DOI: 10.1016/j.pnpbp.2006.02.001

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  21 in total

Review 1.  The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.

Authors:  Marrit K de Boer; Stynke Castelein; Durk Wiersma; Robert A Schoevers; Henderikus Knegtering
Journal:  Schizophr Bull       Date:  2015-02-25       Impact factor: 9.306

2.  A case series: evaluation of the metabolic safety of aripiprazole.

Authors:  Marc De Hert; Linda Hanssens; Ruud van Winkel; Martien Wampers; Dominique Van Eyck; Andre Scheen; Joseph Peuskens
Journal:  Schizophr Bull       Date:  2006-08-29       Impact factor: 9.306

Review 3.  Classifying antipsychotic agents : need for new terminology.

Authors:  Ripu D Jindal; Matcheri S Keshavan
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.

Authors:  Douglas L Boggs; Mohini Ranganathan; Angela A Boggs; Christine M Bihday; Barbara E Peluse; Deepak C D'Souza
Journal:  Prim Care Companion CNS Disord       Date:  2013

Review 5.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

6.  [Not Available].

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

7.  Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth.

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-08

8.  Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth.

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

9.  Treating symptomatic hyperprolactinemia secondary to a long-acting injectable atypical antipsychotic in a patient with bipolar disorder due to an anoxic brain injury.

Authors:  McLeod F Gwynette; Nick Evangelidis
Journal:  Prim Care Companion CNS Disord       Date:  2013

10.  A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder.

Authors:  Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.